Matthew J Loza
Overview
Explore the profile of Matthew J Loza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1021
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thys K, Loza M, Lynn L, Callewaert K, Varma L, Crabbe M, et al.
Sci Rep
. 2024 Oct;
14(1):22981.
PMID: 39362933
We examined candidate biomarkers for efficacy outcomes in hospitalized COVID-19 patients who were treated with sirukumab, an IL-6 neutralizing antibody, in a randomized, double-blind, placebo-controlled, phase 2 trial. Between May...
2.
Taylor P, Schett G, Huizinga T, Wang Q, Ibrahim F, Zhou B, et al.
RMD Open
. 2024 Jun;
10(2).
PMID: 38942592
Objectives: To investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of nipocalimab in participants with moderate to severe active rheumatoid arthritis (RA) and inadequate response or intolerance to ≥1 antitumour necrosis...
3.
Finney L, Avey S, Wiseman D, Rowe A, Loza M, Branigan P, et al.
ERJ Open Res
. 2023 Dec;
9(6).
PMID: 38152081
Background: Early and accurate identification of acute exacerbations of COPD may lead to earlier treatment and prevent hospital admission. Electronic diaries have been developed for symptom monitoring and accelerometers to...
4.
Schett G, Loza M, Palanichamy A, FitzGerald O, Ritchlin C, Bay-Jensen A, et al.
Rheumatol Ther
. 2022 Jul;
9(4):1247-1248.
PMID: 35779224
No abstract available.
5.
Loza M, Nagpal S, Cole S, Laird R, Alcala A, Rao N, et al.
Arthritis Rheumatol
. 2022 Jun;
74(11):1766-1775.
PMID: 35671369
Objective: To identify a panel of serum biomarkers that could specifically identify imminent cases of rheumatoid arthritis (RA) before diagnosis. Methods: Serum samples were collected at 4 time points from...
6.
Schett G, Loza M, Palanichamy A, FitzGerald O, Ritchlin C, Bay-Jensen A, et al.
Rheumatol Ther
. 2022 Mar;
9(4):1017-1030.
PMID: 35352313
Introduction: Guselkumab, a novel interleukin-23p19 subunit monoclonal antibody, has been shown to effectively improve the diverse manifestations of active psoriatic arthritis (PsA) in two phase 3 trials (DISCOVER-1, DISCOVER-2). Serum...
7.
Sweet K, Song Q, Loza M, McInnes I, Ma K, Leander K, et al.
RMD Open
. 2021 May;
7(2).
PMID: 34011674
Objective: To investigate serum protein expression in participants with psoriatic arthritis (PsA) and changes after guselkumab treatment. Methods: Participants with PsA were treated with guselkumab or placebo in the DISCOVER-1...
8.
Cesaroni M, Seridi L, Loza M, Schreiter J, Sweet K, Franks C, et al.
Arthritis Rheumatol
. 2020 Oct;
73(3):472-477.
PMID: 33010188
Objective: In a previously reported phase II randomized, placebo-controlled, interventional trial, we demonstrated that treatment with ustekinumab, an anti-interleukin-12 (IL-12)/IL-23 p40 neutralizing monoclonal antibody, improved global and organ-specific measures of...
9.
Manthey C, Moore B, Chen Y, Loza M, Yao X, Liu H, et al.
PLoS One
. 2019 Nov;
14(11):e0223918.
PMID: 31710624
Background & Aims: Originally believed to be primarily a disorder of T-cell signaling, evidence shows that macrophage-lineage cells also contribute to the pathogenesis of Crohn's disease (CD). Colony stimulating factor-1...
10.
Siebert S, Sweet K, Dasgupta B, Campbell K, McInnes I, Loza M
Arthritis Rheumatol
. 2019 May;
71(10):1660-1669.
PMID: 31070869
Objective: To evaluate the associations of C-reactive protein (CRP) and circulating Th17-associated cytokine levels with psoriatic arthritis (PsA) disease activity and therapeutic response to ustekinumab. Methods: Interleukin-17A (IL-17A), IL-17F, IL-23,...